Table 3 Comparison of clinical factors before and after MAIC of OS in TRANSCEND and JULIET
| Â | Â | Unadjusted | SMD | Adjusted | SMD | Adjusted | SMD |
|---|---|---|---|---|---|---|---|
Mean (SD) age, years | 53.9 (12.9) | 60.3 (13.3) | 0.483 | 61.3 (11.8) | 0.605 | 53.9 (13.1) | 0.000 |
Male sex, % | 61.3 | 66.0 | 0.098 | 66.5 | 0.108 | 61.3 | 0.000 |
IPI score, categorized per JULIET categorization, % | |||||||
 0‒1 | 27.9 | 24.6 | 0.070 | 28.7 | 0.020 | 27.9 | 0.000 |
 2‒5 | 72.1 | 74.6 | – | 70.9 | – | 72.1 | – |
 Missing | 0 | 0.8 | – | 0.3 | – | 0 | – |
ECOG PS score at screening, % | |||||||
 0 | 55.0 | 40.6 | 0.331 | 55.0 | 0.000 | 55.0 | 0.000 |
 1 | 45.0 | 57.8 | – | 45.0 | – | 45.0 | – |
 2 | 0 | 1.6 | – | 0 | – | 0 | – |
Disease stage, % | |||||||
 I or II | 24.3 | 27.0 | 0.066 | 30.5 | 0.141 | 24.3 | 0.000 |
 III or IV | 75.7 | 72.3 | – | 69.2 | – | 75.7 | – |
 Missing | 0 | 0.8 | – | 0.3 | – | 0 | – |
Secondary CNS lymphoma at time of treatment, % | |||||||
 No | 100 | 97.7 | 0.219 | 100 | 0.000 | 100 | 0.000 |
 Yes | 0 | 2.3 | – | 0 | – | 0 | – |
Disease histology, categorized per JULIET categorization, % | |||||||
 DLBCL | 81.1 | 71.1 | 0.397 | 81.1 | 0.000 | 81.1 | 0.000 |
 DLBCL tFL | 18.9 | 22.3 | – | 18.9 | – | 18.9 | – |
 PMBCL | 0 | 5.5 | – | 0 | – | 0 | – |
 FL3B | 0 | 1.2 | – | 0 | – | 0 | – |
Cell of origin, % | |||||||
 GCB | 56.8 | 44.1 | 0.630 | 45.2 | 0.604 | 56.8 | 0.000 |
 ABC | 40.5 | 28.1 | – | 33.2 | – | 40.5 | – |
 Unknown | 2.7 | 21.1 | – | 21.6 | – | 2.7 | – |
 Missing | 0 | 6.6 | – | 0 | – | 0.0 | – |
Double or triple hit, % | |||||||
 Unknown | 36.9 | 29.3 | 0.202 | 28.6 | 0.219 | 37.0 | 0.000 |
 No | 45.9 | 55.9 | – | 56.6 | – | 45.9 | – |
 Yes | 17.1 | 14.8 | – | 14.8 | – | 17.1 | – |
Prior allo-HSCT, % | |||||||
 No | 100 | 97.3 | 0.237 | 100 | 0.000 | 100 | 0.000 |
 Yes | 0 | 2.7 | – | 0 | – | 0 | – |
Prior auto-HSCT, % | |||||||
 No | 51.4 | 66.8 | 0.317 | 51.4 | 0.000 | 51.4 | 0.000 |
 Yes | 48.6 | 33.2 | – | 48.6 | – | 48.6 | – |
Bridging therapy, % | |||||||
 No | 8.1 | 41.4 | 0.837 | 47.4 | 0.977 | 52.4 | 1.101 |
 Yes | 91.9 | 58.6 | – | 52.6 | – | 47.6 | – |
Number of prior lines of therapy, per JULIET definition, % | |||||||
 1 | 4.5 | 0.4 | 0.859 | 0.6 | 0.894 | 0 | 0.315 |
 2 | 44.1 | 19.5 | – | 16.9 | – | 48.7 | – |
 3 | 30.6 | 26.6 | – | 28.0 | – | 30.6 | – |
 4‒6 | 20.7 | 43.4 | – | 46.1 | – | 20.7 | – |
 ≥ 7 | 0 | 9.8 | – | 8.4 | – | 0 | – |
 Missing | 0 | 0.4 | – | 0 | – | 0 | – |
R/R to last therapy, per JULIET definition, % | |||||||
 Refractory | 55.0 | 63.7 | 0.182 | 55.0 | 0.000 | 55.0 | 0.000 |
 Relapsed | 45.0 | 35.9 | – | 45.0 | – | 45.0 | – |
 Missing | 0 | 0.4 | – | 0 | – | 0 | – |
CrCl pre-lymphodepletion, per JULIET criteria, % | |||||||
 < 60 mL/min | 0 | 19.1 | 0.688 | 22.3 | 0.757 | 0 | 0.000 |
 ≥ 60 mL/min | 100 | 80.9 | – | 77.7 | – | 100.0 | – |
LVEF at screening, per JULIET criteria, % | |||||||
 < 45% | 0 | 1.6 | 0.178 | 1.4 | 0.170 | 0 | 0.000 |
 ≥ 45% | 100 | 98.4 | – | 98.6 | – | 100.0 | – |
ALC pre-leukapheresis, per JULIET criteria, % | |||||||
 < 0.3 | 0 | 10.5 | 0.501 | 10.1 | 0.491 | 0 | 0.000 |
 ≥ 0.3 | 100 | 84.0 | – | 83.6 | – | 100.0 | – |
 Missing | 0 | 5.5 | – | 6.3 | – | 0 | – |
Statistics, % | |||||||
 Factors with SMD < 0.2, | – | 29.4 | – | 58.8 | – | 88.2 | – |
 Factors with SMD < 0.1, | – | 17.6 | – | 41.2 | – | 88.2 | – |